ReviewiScience2026
Molecular and neural circuit mechanisms of parvalbumin (PV) neurons in depression: Insights and advances.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interest in parvalbumin (PV) neurons has surged in recent years, driven by new insights into their role in the pathogenesis of depression. As a key class of γ-aminobutyric acid (GABA)-ergic interneurons, PV neurons have emerged as critical regulators of excitatory-inhibitory (E/I) balance, a core mechanism disrupted in depression. Growing evidence links PV neuron dysfunction to mood disturbances and cognitive impairments in depression. Recent studies highlight molecular alterations in PV neurons, including gene regulation, epigenetic modifications, and neurotransmitter/receptor imbalances, as well as circuit dysfunctions in the medial prefrontal cortex, hippocampus, and amygdala in depression. Interventions targeting PV neurons, such as pharmacological agents, neurotrophic factor modulation, and neuromodulation, show promise in restoring function. This review summarizes current advances in the molecular and circuit mechanisms of PV neuron dysfunction in depression, with the aim of providing a useful reference for future related studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.